Dr. Kapil Dhingra, M.D
Dr. Dhingra brings extensive experience in the clinical and strategic development of ADCs and targeted therapeutics, having served as a board member and advisor to numerous oncology companies involved in transformative acquisitions by Amgen, Bayer, and Novartis. As Vice President and Head of Oncology Clinical Development at Hoffmann-La Roche, he contributed to building what became the global leader in oncology. Since founding KAPital Consulting in 2008, Dr. Dhingra has advised companies across the US, Europe, and Australasia, and has served on the boards of publicly listed companies including Micromet, Algeta, Advanced Accelerator Applications, Autolus, Replimune, Five Prime, LAVA Therapeutics, CARGO Therapeutics, and, Black Diamond. He completed his Haematology-Oncology fellowship at Emory University and held faculty positions at M.D. Anderson Cancer Center, Indiana University School of Medicine, and Memorial Sloan Kettering Cancer Center. He is the author or co-author of more than 100 publications and abstracts.
